subscribeSubscribe
Amylyx stock slips 6% after phase 2 rare disease data drop

Amylyx stock slips 6% after phase 2 rare disease data drop
Gabrielle Masson FIERCE BIOTECH
11 Apr 2024
Share Share
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers

Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
PRESS RELEASE
05 Apr 2024
Share Share
Amylyx Announces to Remove RELYVRIO®/ALBRIOZA™ from the Market

Amylyx Announces to Remove RELYVRIO®/ALBRIOZA™ from the Market
BUSINESSWIRE
04 Apr 2024
Share Share
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GLOBENEWSWIRE
28 Mar 2024
Share Share
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
PRESS RELEASE
09 Mar 2024
Share Share
Pheburane is now on the Medicaid Preferred Drug List in 10 states

Pheburane is now on the Medicaid Preferred Drug List in 10 states
PR NEWSWIRE
23 Jan 2024
Share Share
RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND

RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND
BUSINESSWIRE
27 Nov 2023
Share Share
Pheburane coverage to reach ~80% of commercially insured US patients

Pheburane coverage to reach ~80% of commercially insured US patients
GLOBENEWSWIRE
26 Oct 2023
Share Share
Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again

Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again
Zoey Becker FIERCE PHARMA
14 Oct 2023
Share Share
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual NEALS Meeting

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual NEALS Meeting
BUSINESSWIRE
02 Oct 2023
Share Share